FDA Ends 35-Year Rule Making Key Schizophrenia Drug Easier to Get

Clozapine REMS Eliminated After 35 Years Boosting Schizophrenia Treatment Access

Topline

The FDA's recent decision to eliminate the mandatory Clozapine Risk Evaluation and Mitigation Strategy (REMS) program represents a significant change, potentially improving treatment accessibility for individuals with treatment-resistant schizophrenia (TRS).

Study Details:

Schizophrenia impacts approximately 1% of the US population, with nearly ha…